Trifocal intraocular lenses versus bifocal intraocular lenses after cataract extraction among participants with presbyopia.


Journal

The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747

Informations de publication

Date de publication:
27 01 2023
Historique:
pmc-release: 27 01 2024
entrez: 27 1 2023
pubmed: 28 1 2023
medline: 1 2 2023
Statut: epublish

Résumé

Presbyopia occurs when the lens of the eyes loses its elasticity leading to loss of accommodation. The lens may also progress to develop cataract, affecting visual acuity and contrast sensitivity. One option of care for individuals with presbyopia and cataract is the use of multifocal or extended depth of focus intraocular lens (IOL) after cataract surgery. Although trifocal and bifocal IOLs are designed to restore three and two focal points respectively, trifocal lens may be preferable because it restores near, intermediate, and far vision, and may also provide a greater range of useful vision and allow for greater spectacle independence in individuals with presbyopia. To assess the effectiveness and safety of implantation with trifocal versus bifocal IOLs during cataract surgery among people with presbyopia. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2022, Issue 3); Ovid MEDLINE; Embase.com; PubMed; ClinicalTrials.gov; and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP). We did not use any date or language restrictions in the electronic search for trials. We last searched the electronic databases on 31 March 2022.  SELECTION CRITERIA: We included randomized controlled trials that compared trifocal and bifocal IOLs among participants 30 years of age or older with presbyopia undergoing cataract surgery. We used standard Cochrane methodology and graded the certainty of the body of evidence according to the GRADE classification. We identified seven studies conducted in Europe and Turkey with a total of 331 participants. All included studies assessed visual acuity using a logarithm of the minimum angle of resolution (LogMAR chart). Of them, six (86%) studies assessed uncorrected distance visual acuity (the primary outcome of this review). Some studies also examined our secondary outcomes including uncorrected near, intermediate, and best-corrected distance visual acuity, as well as contrast sensitivity. Study characteristics All participants had bilateral cataracts with no pre-existing ocular pathologies or ocular surgery. Participants' mean age ranged from 55 to 74 years. Three studies reported on gender of participants, and they were mostly women. We assessed all of the included studies as being at unclear risk of bias for most domains. Two studies received financial support from manufacturers of lenses evaluated in this review, and at least one author of another study reported receiving payments for delivering lectures with lens manufacturers. Findings All studies compared trifocal versus bifocal IOL implantation on visual acuity outcomes measured on a LogMAR scale. At one year, trifocal IOL showed no evidence of effect on uncorrected distance visual acuity (mean difference (MD) 0.00, 95% confidence interval (CI) -0.04 to 0.04; I We found low-certainty of evidence that compared with bifocal IOL, implantation of trifocal IOL may improve uncorrected intermediate visual acuity at one year. However, there was no evidence of a difference between trifocal and bifocal IOL for uncorrected distance visual acuity, uncorrected near visual acuity, and best-corrected visual acuity at one year. Future research should include the comparison of both trifocal IOL and specific bifocal IOLs that correct intermediate visual acuity to evaluate important outcomes such as contrast sensitivity, quality of life, and vision-related adverse effects.

Sections du résumé

BACKGROUND
Presbyopia occurs when the lens of the eyes loses its elasticity leading to loss of accommodation. The lens may also progress to develop cataract, affecting visual acuity and contrast sensitivity. One option of care for individuals with presbyopia and cataract is the use of multifocal or extended depth of focus intraocular lens (IOL) after cataract surgery. Although trifocal and bifocal IOLs are designed to restore three and two focal points respectively, trifocal lens may be preferable because it restores near, intermediate, and far vision, and may also provide a greater range of useful vision and allow for greater spectacle independence in individuals with presbyopia.
OBJECTIVES
To assess the effectiveness and safety of implantation with trifocal versus bifocal IOLs during cataract surgery among people with presbyopia.
SEARCH METHODS
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2022, Issue 3); Ovid MEDLINE; Embase.com; PubMed; ClinicalTrials.gov; and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP). We did not use any date or language restrictions in the electronic search for trials. We last searched the electronic databases on 31 March 2022.  SELECTION CRITERIA: We included randomized controlled trials that compared trifocal and bifocal IOLs among participants 30 years of age or older with presbyopia undergoing cataract surgery.
DATA COLLECTION AND ANALYSIS
We used standard Cochrane methodology and graded the certainty of the body of evidence according to the GRADE classification.
MAIN RESULTS
We identified seven studies conducted in Europe and Turkey with a total of 331 participants. All included studies assessed visual acuity using a logarithm of the minimum angle of resolution (LogMAR chart). Of them, six (86%) studies assessed uncorrected distance visual acuity (the primary outcome of this review). Some studies also examined our secondary outcomes including uncorrected near, intermediate, and best-corrected distance visual acuity, as well as contrast sensitivity. Study characteristics All participants had bilateral cataracts with no pre-existing ocular pathologies or ocular surgery. Participants' mean age ranged from 55 to 74 years. Three studies reported on gender of participants, and they were mostly women. We assessed all of the included studies as being at unclear risk of bias for most domains. Two studies received financial support from manufacturers of lenses evaluated in this review, and at least one author of another study reported receiving payments for delivering lectures with lens manufacturers. Findings All studies compared trifocal versus bifocal IOL implantation on visual acuity outcomes measured on a LogMAR scale. At one year, trifocal IOL showed no evidence of effect on uncorrected distance visual acuity (mean difference (MD) 0.00, 95% confidence interval (CI) -0.04 to 0.04; I
AUTHORS' CONCLUSIONS
We found low-certainty of evidence that compared with bifocal IOL, implantation of trifocal IOL may improve uncorrected intermediate visual acuity at one year. However, there was no evidence of a difference between trifocal and bifocal IOL for uncorrected distance visual acuity, uncorrected near visual acuity, and best-corrected visual acuity at one year. Future research should include the comparison of both trifocal IOL and specific bifocal IOLs that correct intermediate visual acuity to evaluate important outcomes such as contrast sensitivity, quality of life, and vision-related adverse effects.

Identifiants

pubmed: 36705482
doi: 10.1002/14651858.CD012648.pub3
pmc: PMC9881452
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

CD012648

Subventions

Organisme : NEI NIH HHS
ID : U01 EY020522
Pays : United States

Commentaires et corrections

Type : UpdateOf

Informations de copyright

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Références

J Cataract Refract Surg. 2006 Oct;32(10):1650-6
pubmed: 17010862
Vision Res. 1999 Jun;39(11):1991-2015
pubmed: 10343784
Jpn J Ophthalmol. 2019 Nov;63(6):429-436
pubmed: 31641897
J Cataract Refract Surg. 2019 May;45(5):587-594
pubmed: 30853317
Eur J Ophthalmol. 2017 Jun 26;27(4):460-465
pubmed: 28165609
Epidemiol Rev. 1995;17(2):336-46
pubmed: 8654515
Int Ophthalmol. 2020 Feb;40(2):351-359
pubmed: 31583551
BMC Ophthalmol. 2014 Jul 24;14:94
pubmed: 25060855
J Cataract Refract Surg. 2013 Jul;39(7):1093-9
pubmed: 23692884
Clin Ophthalmol. 2012;6:1459-66
pubmed: 23055664
J Refract Surg. 2021 Feb 1;37(2):98-104
pubmed: 33577695
Rom J Ophthalmol. 2015 Apr-Jun;59(2):100-2
pubmed: 26978870
Clin Ophthalmol. 2022 Mar 04;16:619-629
pubmed: 35282170
J Cataract Refract Surg. 2001 Feb;27(2):261-6
pubmed: 11226793
Dtsch Arztebl Int. 2009 Oct;106(43):695-702
pubmed: 19946433
J Cataract Refract Surg. 2013 Mar;39(3):343-9
pubmed: 23332118
J Ophthalmol. 2015;2015:962891
pubmed: 26301104
Sci Rep. 2017 Mar 28;7:45337
pubmed: 28422087
J Refract Surg. 2018 Apr 1;34(4):273-280
pubmed: 29634843
Sci Rep. 2020 Sep 9;10(1):14832
pubmed: 32908159
Korean J Ophthalmol. 2019 Aug;33(4):333-342
pubmed: 31389209
J Fr Ophtalmol. 2012 May;35(5):338-42
pubmed: 22424593
Cochrane Database Syst Rev. 2020 Jun 18;6:CD012648
pubmed: 32584432
Clin Ophthalmol. 2013;7:1957-65
pubmed: 24124348
Int J Ophthalmol. 2017 Oct 18;10(10):1528-1533
pubmed: 29062771
Int J Ophthalmol. 2021 Mar 18;14(3):356-365
pubmed: 33747809
Int Ophthalmol. 2020 Feb;40(2):393-401
pubmed: 31624988
PLoS One. 2017 Oct 26;12(10):e0186522
pubmed: 29073156
J Fr Ophtalmol. 2000 Apr;23(4):355-9
pubmed: 10794984
PLoS One. 2015 Aug 19;10(8):e0136218
pubmed: 26287670
Sci Rep. 2021 Jun 8;11(1):12081
pubmed: 34103624
Int J Ophthalmol. 2021 Dec 18;14(12):1876-1881
pubmed: 34926202
Eur J Ophthalmol. 2021 May;31(3):1014-1020
pubmed: 32460552
Clin Ophthalmol. 2012;6:1421-7
pubmed: 22969289
Clin Exp Ophthalmol. 2018 May;46(4):380-388
pubmed: 29044974
J Refract Surg. 2016 Oct 1;32(10):659-663
pubmed: 27722752
Eur J Ophthalmol. 2014 Jul-Aug;24(4):501-8
pubmed: 24366771
Clin Ophthalmol. 2021 Mar 04;15:983-990
pubmed: 33692612
Br J Ophthalmol. 1998 Aug;82(8):971-3
pubmed: 9828786
J Refract Surg. 2014 Oct;30(10):666-72
pubmed: 25291749
Cochrane Database Syst Rev. 2012 Sep 12;(9):CD003169
pubmed: 22972061
Clin Ophthalmol. 2014 Oct 14;8:2105-13
pubmed: 25342881
J Refract Surg. 2020 Aug 1;36(8):528-535
pubmed: 32785726
Br J Ophthalmol. 2004 Jan;88(1):11-6
pubmed: 14693761
Clin Ophthalmol. 2022 Jan 18;16:145-152
pubmed: 35082481
Klin Oczna. 1999;101(6):437-9
pubmed: 10786051
Ophthalmology. 2015 Sep;122(9):e56-7
pubmed: 26299730
J Refract Surg. 2017 Oct 1;33(10):655-662
pubmed: 28991332
J Refract Surg. 2016 Mar;32(3):146-51
pubmed: 27027620
J Korean Med Sci. 2018 Sep 27;33(44):e275
pubmed: 30369857
J Cataract Refract Surg. 2015 Aug;41(8):1631-40
pubmed: 26432120
Ophthalmology. 2015 Apr;122(4):700-10
pubmed: 25537197
Front Med (Lausanne). 2021 Sep 30;8:647268
pubmed: 34660614
Int J Ophthalmol. 2018 Mar 18;11(3):484-492
pubmed: 29600184
Eye (Lond). 2002 Jul;16(4):481-90
pubmed: 12101459
Syst Rev. 2013 Sep 23;2:81
pubmed: 24059250
Middle East Afr J Ophthalmol. 2014 Jan-Mar;21(1):10-7
pubmed: 24669140
BMC Ophthalmol. 2019 Mar 14;19(1):78
pubmed: 30871503
J Cataract Refract Surg. 2002 Nov;28(11):1957-63
pubmed: 12457669
J Cataract Refract Surg. 2019 Nov;45(11):1625-1636
pubmed: 31706517
Graefes Arch Clin Exp Ophthalmol. 2010 Sep;248(9):1299-306
pubmed: 20526609
BMC Ophthalmol. 2015 Aug 21;15:110
pubmed: 26292964

Auteurs

Diego Zamora-de La Cruz (D)

Anterior Segment Department, Instituto de Oftalmología Fundación Conde de Valenciana, Mexico City, Mexico.

John Bartlett (J)

Jules Stein Eye Institute, UCLA, Los Angeles, California, USA.

Mario Gutierrez (M)

Retina and Vitreous Department, Instituto de Oftalmología Fundación Conde de Valenciana, Mexico City, Mexico.

Sueko M Ng (SM)

Department of Ophthalmology, University of Colorado Denver - Anschutz Medical Campus, Aurora, Colorado, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH